BACKGROUND: Nearly half of perinatal HIV infection is preventable with nevirapine (NVP), which has transformed the ability to confront this transmission route in resource-limited settings. METHODS: A NVP-based perinatal HIV prevention program initiated in Lusaka, Zambia in November 2001. RESULTS: The first 12 months cost US$221 000 and enabled 178 district health employees to be trained in voluntary counseling and testing: 17 263 pregnant women were counseled for HIV, 12 438 (72%) were tested, and 2924 (24%) were found to be infected with HIV. NVP has been taken by 1654 (57%) mothers and 1157 (40%) babies. It is estimated that at least 190 infants have been spared HIV infection (11 per 1000 counseled women or 65 per 1000 identified HIV-infected women). CONCLUSIONS: Prevention of mother-to-child HIV transmission is feasible and cost effective in resource-limited settings. In Lusaka, thousands of women have received voluntary counseling and testing and NVP therapy under the present scheme. Patient attrition and non-adherence represented a major source of program inefficiency, which requires to be systematically addressed.
BACKGROUND: Nearly half of perinatal HIV infection is preventable with nevirapine (NVP), which has transformed the ability to confront this transmission route in resource-limited settings. METHODS: A NVP-based perinatal HIV prevention program initiated in Lusaka, Zambia in November 2001. RESULTS: The first 12 months cost US$221 000 and enabled 178 district health employees to be trained in voluntary counseling and testing: 17 263 pregnant women were counseled for HIV, 12 438 (72%) were tested, and 2924 (24%) were found to be infected with HIV. NVP has been taken by 1654 (57%) mothers and 1157 (40%) babies. It is estimated that at least 190 infants have been spared HIV infection (11 per 1000 counseled women or 65 per 1000 identified HIV-infectedwomen). CONCLUSIONS: Prevention of mother-to-child HIV transmission is feasible and cost effective in resource-limited settings. In Lusaka, thousands of women have received voluntary counseling and testing and NVP therapy under the present scheme. Patient attrition and non-adherence represented a major source of program inefficiency, which requires to be systematically addressed.
Authors: K M De Cock; M G Fowler; E Mercier; I de Vincenzi; J Saba; E Hoff; D J Alnwick; M Rogers; N Shaffer Journal: JAMA Date: 2000-03-01 Impact factor: 56.272
Authors: Jeffrey S A Stringer; Moses Sinkala; Julia P Stout; Robert L Goldenberg; Edward P Acosta; Victoria Chapman; Rosemary Kumwenda-Phiri; Sten H Vermund Journal: J Acquir Immune Defic Syndr Date: 2003-04-15 Impact factor: 3.731
Authors: Jeffrey S A Stringer; Moses Sinkala; Dwight J Rouse; Robert L Goldenberg; Sten H Vermund Journal: Am J Public Health Date: 2002-03 Impact factor: 9.308
Authors: L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson Journal: Lancet Date: 1999-09-04 Impact factor: 79.321
Authors: J S Stringer; D J Rouse; S H Vermund; R L Goldenberg; M Sinkala; A A Stinnett Journal: J Acquir Immune Defic Syndr Date: 2000-08-01 Impact factor: 3.731
Authors: Marco T Luque; Cathy A Jenkins; Bryan E Shepherd; Denis Padgett; Vanessa Rouzier; Regina Célia M Succi; Daisy M Machado; Catherine C McGowan; Sten H Vermund; Jorge A Pinto Journal: J Pediatr Date: 2017-01-09 Impact factor: 4.406
Authors: Cristina M Marazzi; Paola Germano; Giuseppe Liotta; Giovanni Guidotti; Sandra Loureiro; Aurelio da Cruz Gomes; Maria C Valls Blazquez; Pasquale Narciso; Carlo F Perno; Sandro Mancinelli; Annamaria Doro Altan; Karin Nielsen-Saines; Leonardo Palombi Journal: Eur J Pediatr Date: 2007-01-18 Impact factor: 3.183
Authors: Katherine C Liu; Jessica Mulindwa; Mark J Giganti; Nande B Putta; Namwinga Chintu; Benjamin H Chi; Jeffrey S A Stringer; Elizabeth M Stringer Journal: J Acquir Immune Defic Syndr Date: 2011-08-15 Impact factor: 3.731
Authors: Dara Potter; Robert L Goldenberg; Ann Chao; Moses Sinkala; Alain Degroot; Jeffrey S A Stringer; Marc Bulterys; Sten H Vermund Journal: J Acquir Immune Defic Syndr Date: 2008-01-01 Impact factor: 3.731